(Q37553571)

21 August 2017

1 reference

title

State-of-the-art review: Assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxis (English)

1 reference

21 August 2017

1 reference

1 reference

Russell D Hull

1

1 reference

21 August 2017

Roger D Yusen

series ordinal

2

1 reference

21 August 2017

David Bergqvist

series ordinal

3

1 reference

21 August 2017

publication date

15 July 2009

1 reference

Clinical and Applied Thrombosis-Hemostasis

21 August 2017

published in

1 reference

21 August 2017

volume

15

1 reference

21 August 2017

issue

4

1 reference

21 August 2017

page(s)

377-388

1 reference

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

Low molecular weight heparin in prevention of perioperative thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

Meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609338712

21 January 2018

Identifiers

DOI

10.1177/1076029609338712

1 reference

21 August 2017

1 reference